Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians.
Citrome LeslieEmily BelcherSylvie StacyMark SuettMarko MychaskiwGregory D SalinasPublished in: Neuropsychiatric disease and treatment (2022)
This study suggests that clinicians may be reluctant to discuss or recommend switching patients to an LAI antipsychotic medication if they are perceived as doing well on current therapy. These results will inform future research and continuing education that aims to improve the confidence, knowledge, and competence of clinicians who provide care for patients with schizophrenia who may benefit from treatment with an LAI antipsychotic medication and clinicians who may be more likely to routinely offer an LAI antipsychotic medication to their patients.
Keyphrases
- healthcare
- end stage renal disease
- palliative care
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- stem cells
- peritoneal dialysis
- adverse drug
- patient reported outcomes
- mesenchymal stem cells
- quality improvement
- bone marrow
- cell therapy
- social support
- health insurance
- drug induced
- replacement therapy